Docetaxel - CLL PHARMAAlternative Names: SYN 2004
Latest Information Update: 01 Jun 2016
At a glance
- Originator CLL PHARMA
- Class Antineoplastics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Jun 2016 Chemical structure information added
- 31 May 2016 Preclinical trials in Cancer in France (unspecified route) before May 2016